NewzNovartis presented clinical trial data on Friday demonstrating that its multiple sclerosis treatment reduced relapse rates by one-third compared to a standard therapy. The findings were shared as part of a pivotal study evaluating the drug's efficacy in managing the condition.
While the treatment showed clear clinical benefits, its efficacy levels remain lower than those reported for a competing drug developed by Roche. However, the data suggests that the Novartis treatment offers a more favorable safety profile, providing an alternative consideration for patients and clinicians weighing performance against potential side effects.
In-depth summary · AI, neutral